The GABAA receptor alpha-3 subunit (GABRA3) is a critical component of GABAA receptors, ligand-gated chloride channels mediating inhibitory neurotransmission in the central nervous system. Encoded by the *GABRA3* gene, this subunit assembles with other subunits (e.g., β, γ) to form receptor subtypes with distinct pharmacological and electrophysiological properties. GABRA3-containing receptors are predominantly expressed in brain regions such as the thalamus, cortex, and limbic system, influencing neural circuits related to anxiety, sleep, and cognitive functions. Antibodies targeting GABRA3 are essential tools for studying its expression, localization, and role in physiological or pathological contexts. They are widely used in techniques like immunohistochemistry, Western blotting, and immunofluorescence to map receptor distribution in tissues or assess changes in neurological disorders. Dysregulation of GABRA3 has been implicated in conditions like epilepsy, neurodevelopmental disorders, and chronic pain, making its antibody valuable for mechanistic research. Additionally, GABRA3 antibodies aid in exploring the subunit-specific effects of therapeutics, such as benzodiazepines, which selectively modulate GABAA receptor subtypes. Robust validation of these antibodies is crucial to ensure specificity, given the high homology among GABAA receptor subunits.